Interleukin‑23 versus Interleukin‑17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real‑World Comparison From the TriNetX US Collaborative Network
BioDrugs. 2025 Mar;39(2):297-306 doi: 10.1007/s40259-025-00705-5
With their comparative effectiveness in preventing PsA unclear, Yu S, et al. conducted a retrospective cohort study to compare the occurrence of developing incidental PsA among PsO patients treated with IL23is or IL17is. Their findings suggest that IL23is may be a more suitable treatment option for patients with PsO at higher risk of PsA.
Keywords:
